RTI Surgical®’s Post

Market research and competitive intelligence stand as crucial pillars in strategic planning. At #ASCO23, we engaged with dozens of KOL's and 30 companies dedicated to advancing liquid biopsies' development and commercialization in the clinic. Notably, survey results revealed that 60% of respondents believe liquid biopsies won't replace traditional tissue biopsies, but intriguingly, 40% suggested that they might. For a downloadable summary of this research, click here: https://lnkd.in/eSssEaDg #liquidbiopsy #marketresearch #competitiveintelligence #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference

A First Step into bringing Novel US FDA Breakthrough technology to the US , A Giant Leap of Hope & Promise for US based Patients suffering from complex Coronary occlusive vascular disease . Concept Medical is proud to announce commencement of its Pivotal US FDA Investigational Devise Exemption Study for the treatment of Instent Restenosis with Magic Touch SCB - The World's 1st CE commercialized Novel Sirolimus Drug Coated Balloon , offering a safer and effective alternative for treatment of complex coronary disease such as InStent Restenosis . We are thankful to Dr Ajay Kirtane , Dr Azeem Latib , the principal investigators of the study and all the US study investigators supporting the enrollment and treatment in this pivotal multi- centered Randomised clinical trial. With Over 23K patients touched with Its clinical trial program with results that are altering standards of care and shaping the future of percutaneous treatment of occlusive vascular disease with over 180 K patients treated in real world setting with its solutions accross vascular disease , this milestone is indeed an important step to extend these proven technlogies to ailing patients in the US # Worlds 1st CE commercialized Sirolimus DCB #US FDA Breakthrough Devices # Largest and Longest Studied Clinical trial program touching over 23 K patients # over 180 K patients treated - Confidence Inspired by Real World Use.

Last month during his speech at the MarketsandMarkets™ Next-Gen Digital Pathology Conference, our founder Matthew O. Leavitt, MD shared the inspiration behind the creation of Lumea's pre-analytical technology: "We realized that to change the world of digital pathology, you really have to understand the physical worlds that feed into it – and that starts with the patient in the clinic." Driven by this patient-centric approach, Leavitt and his team dedicated themselves to inventing better tissue-handling tools that have reduced QNS rates, minimized tissue damage like fragmentation and curling, reduced linear variability, and resulted in many other incredible benefits. See it for yourself: https://lnkd.in/gp-fjXSj

exosmart™: a Class IIa medical device revolutionizing regenerative medicine. 🌟 Using cutting-edge ultrafiltration technology, it selectively concentrates plasma or saline solutions. Designed to harvest and hyper-concentrate autologous exosomes from peripheral blood, bone marrow concentrate, and adipose tissue. Elevate your practice with exosmart™. 💡 #RegenerativeMedicine #Innovation #exosmart #exosome #regenerativemedicine #medicalinnovation

KFBIO team brings a series of revolutionary functions to the new digital pathology scanner KF-PRX-1200 🔬 Bridging Brightfield & Fluorescence, Scanning & Storage - All in One! Our KF-PRX-1200 seamlessly combines Brightfield and Fluorescence scanning, making it a versatile solution for a wide range of applications. With this scanner, you can have the best of both worlds in a single, compact device. 🔍 Double the Efficiency: Simultaneous Scanning of Two Slides! What sets the KF-PRX-1200 apart is its ability to scan two slides at the same time, enhancing your lab's productivity and workflow efficiency. 📦 Massive Throughput: 1200 Slides in a Single Batch! Imagine the convenience of processing up to 1200 slides in a single batch. Our scanner is designed to handle large workloads with ease. ⚙️ Uninterrupted Workflow: Scan Up to 4800 Slides in a Day! With the KF-PRX-1200, you can achieve an impressive daily scanning capacity of up to 4800 slides, ensuring your lab operations run smoothly without bottlenecks. 🔄 Continuous Loading: No More Halt in Operations! Our scanner is engineered for continuous loading, so you can keep the pace going without any interruptions. This is a significant step forward in pathology diagnostics, and we can't wait to see the positive impact it will have on labs and healthcare professionals. Stay tuned for the official presentation and be prepared to witness the future of digital pathology! #KFBIO #DigitalPathology #PathologyInnovation #KFPRX1200 #HealthcareTechnology

Market research and competitive intelligence stand as crucial pillars in strategic planning. At #ASCO23, we engaged with dozens of KOL's and 30 companies dedicated to advancing liquid biopsies' development and commercialization in the clinic. Notably, survey results revealed that 60% of respondents believe liquid biopsies won't replace traditional tissue biopsies, but intriguingly, 40% suggested that they might. For a downloadable summary of this research, click here: https://lnkd.in/enJX8jEE #liquidbiopsy #marketresearch #competitiveintelligence #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference

🩺 Introducing Exosmart: Elevating Regenerative Medicine! 🚀 Exosmart, a remarkable Class IIa medical device, is here to revolutionize regenerative medicine with cutting-edge technology. 💡 This innovative system is designed for selective plasma and saline solution concentration using ultrafiltration, making it a game-changer in medical science. 🌡 But that's not all! Exosmart is your go-to solution for collecting and super-concentrating autologous exosomes from peripheral blood, bone marrow concentrate, and adipose tissue. 🧬 Say hello to the future of regenerative medicine! 🌟 #Exosmart #RegenerativeMedicine #MedicalInnovation

Discover the pathology service you've been searching for - fast, accurate, and reliable! We take you from tissue processing to deep image analysis with meticulous precision, ensuring efficiency without sacrificing quality. Why sets us apart? 🚀 Speed: Experience rapid results with high-throughput capabilities. 🧬 Reliability: Trust in our extensive range of over 400 IHC validated markers. 🤖 Tech-Forward: Benefit from our state-of-the-art platforms and automated workflows. ✅ Expertise: Count on our expert team for analyses that are spot-on every time. Bid farewell to delays and embrace a seamless transition from discovery to development. Learn more ➡️ https://bit.ly/3T0LTef #DigitalPathology #InSituHybridization

exosmart™: a Class IIa medical device revolutionizing regenerative medicine. 🌟 Using cutting-edge ultrafiltration technology, it selectively concentrates plasma or saline solutions. Designed to harvest and hyper-concentrate autologous exosomes from peripheral blood, bone marrow concentrate, and adipose tissue. Elevate your practice with exosmart™. 💡 #RegenerativeMedicine #Innovation #exosmart #exosome #regenerativemedicine #medicalinnovation

Auctus Surgical, Inc. company dedicated to revolutionizing scoliosis treatment. Their mission is clear: develop cutting-edge technologies for non-fusion scoliosis correction, enabling non-surgical dynamic adjustments of implants over time. Their game-changing solution, the Auctus Dynamic Tethering System, boasts dynamic tension and allows complete non-surgical adjustment. It's proven to be the most effective method for making gradual adjustments over time, all while preventing over-correction and acting as an internal brace. This breakthrough technology is set to redefine how we approach scoliosis, offering a more tailored, patient-centric solution. Sophisticated investors are invited to find out more on this link: https://lnkd.in/druw3bMy #sophisticatedinvestors